These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 20933432)

  • 1. Efficient production of therapeutic doses of [131I]-metaiodobenzylguanidine for clinical use.
    Prabhakar G; Mathur A; Shunmugam G; Teje YD; Sachdev SS; Sivaprasad N
    Appl Radiat Isot; 2011 Jan; 69(1):63-7. PubMed ID: 20933432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
    Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
    Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
    Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
    Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG.
    Brogsitter C; Pinkert J; Bredow J; Kittner T; Kotzerke J
    J Nucl Med; 2005 Dec; 46(12):2112-6. PubMed ID: 16330578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A gene therapy/targeted radiotherapy strategy for radiation cell kill by.
    Boyd M; Mairs RJ; Cunningham SH; Mairs SC; McCluskey A; Livingstone A; Stevenson K; Brown MM; Wilson L; Carlin S; Wheldon TE
    J Gene Med; 2001; 3(2):165-72. PubMed ID: 11318115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
    Rose B; Matthay KK; Price D; Huberty J; Klencke B; Norton JA; Fitzgerald PA
    Cancer; 2003 Jul; 98(2):239-48. PubMed ID: 12872341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a fast and high yield method for routine production of [(131) I]MIBG and investigation of its radiochemical stability for diagnosis and treatment uses.
    Davarpanah MR; Attar Nosrati S; Khoshhosn HA; Fazlali M; Kazemi Boudani M
    J Labelled Comp Radiopharm; 2013 Nov; 56(13):686-8. PubMed ID: 25196031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
    Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
    J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience.
    Shapiro B; Sisson JC; Wieland DM; Mangner TJ; Zempel SM; Mudgett E; Gross MD; Carey JE; Zasadny KR; Beierwaltes WH
    J Nucl Biol Med (1991); 1991; 35(4):269-76. PubMed ID: 1823834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updating the procedure for metaiodobenzylguanidine labelling with iodine radioisotopes employed in industrial production.
    Franceschini R; Mosca R; Bonino C
    J Nucl Biol Med (1991); 1991; 35(4):183-5. PubMed ID: 1823814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraarterial 131I-MIBG therapy of neuroendocrine tumors with liver metastases.
    Popp M; Strumpf A; Zöphel K; Stroszczynski C; Kotzerke J
    Nuklearmedizin; 2010; 49(1):N2-3. PubMed ID: 20336828
    [No Abstract]   [Full Text] [Related]  

  • 12. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
    Boyd M; Sorensen A; McCluskey AG; Mairs RJ
    J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolution in the use of MIBG in more than 25 years of experimental and clinical applications.
    Rufini V; Shulkin B
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):341-50. PubMed ID: 19088689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspects on radionuclide therapy in malignant pheochromocytomas.
    Forssell-Aronsson E; Bernhardt P; Wängberg B; Kölby L; Nilsson O; Ahlman H
    Ann N Y Acad Sci; 2006 Aug; 1073():498-504. PubMed ID: 17102117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
    Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 131I-MIBG therapy of neural crest tumours (review).
    Troncone L; Rufini V
    Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.
    Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman J; Onaitis MW; Tyler DS; Olson JA
    Cancer; 2004 Nov; 101(9):1987-93. PubMed ID: 15455358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors.
    Grünwald F; Ezziddin S
    Semin Nucl Med; 2010 Mar; 40(2):153-63. PubMed ID: 20113683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology.
    Vallabhajosula S; Nikolopoulou A
    Semin Nucl Med; 2011 Sep; 41(5):324-33. PubMed ID: 21803182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear medicine therapy of pheochromocytoma and paraganglioma.
    Troncone L; Rufini V
    Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.